Showing 5631-5640 of 9117 results for "".
- Ilumya Now Available for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/ilumya-now-available-for-moderate-to-severe-plaque-psoriasis/2457534/Ilumya™ (tildrakizumab-asmn) 100mg/mL from Sun Pharmaceutical Industries Ltd. is now available in the United States. Ilumya is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for s
- Opdivo Plus Yervoy Demonstrates Durable Four-Year Survival Benefits in Advanced Melanomahttps://practicaldermatology.com/news/opdivo-plus-yervoy-demonstrates-durable-four-year-survival-benefits-in-advanced-melanoma/2457552/Four-year data from the Phase 3 CheckMate-067 clinical trial—the longest follow-up to date—continue to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in
- New from xMedica: Aesthetics Conference Features Energy Based Treatments for Male and Female Sexual Wellnesshttps://practicaldermatology.com/news/new-from-xmedica-aesthetics-conference-features-energy-based-treatments-for-male-and-female-sexual-wellness/2457553/Medical education consortium xMedica LLC of Atlanta has developed a new educational initiative, "The Use of Energy-Based Devices for Improving Sexual Health." The overriding goal of this unique conference is to present factual data in a CME setting to address this new are
- Amgevita, Amgen's Biosimilar Adalimumab, Launches in Europehttps://practicaldermatology.com/news/amgevita-amgens-biosimilar-adalimumab-launches-in-europe/2457555/Amgen's Amgevita, a biosimilar to adalimumab, has launched in markets across Europe. Amgevita is the first adalimumab biosimilar to be approved by the European Commission (EC) and is authorized for the treatment of inflammatory diseases in adults, including moder
- Residents of Distinction Attend 2018 Coastal Dermatology Symposiumhttps://practicaldermatology.com/news/residents-of-distinction-attend-2018-coastal-dermatology-symposium/2457554/As part of the dermMentors Resident of Distinction Award program, sponsored by Beiersdorf Inc., five dermatology residents attended the 14th Annual Coastal Dermatology Symposium, held in Monterey, CA October 3-6, 2018. The 2018 dermMentors™
- Almirall's Seysara Set to Shake Up US Acne Markethttps://practicaldermatology.com/news/almiralls-seysara-set-to-shake-up-us-acne-market/2457557/The US Food and Drug Administration’s approval of Almirall’s Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ages nine and older is set to shake up the currently stagnant acne market due to its ease of adminis
- Real-world Evaluation Study Confirms Benefits of ARTAS iX Robotic Hair Restoration Systemhttps://practicaldermatology.com/news/real-world-evaluation-study-confirms-benefits-of-artas-ix-robotic-hair-restoration-system/2457560/Restoration Robotics, Inc. (NASDAQ: HAIR), the global leader in robotic hair restoration, today announced results from a real-world evaluation study. The new ARTAS iX™ Robotic Hair Restoration System demonstrates clinical efficiency in hair harvesting and implanta
- Aclaris Acquires Rhofade from Allerganhttps://practicaldermatology.com/news/aclaris-acquires-rhofade-from-allergan/2457561/Aclaris Therapeutics, Inc. has entered into a definitive asset purchase agreement with Allergan Sales, LLC to acquire worldwide rights to Rhofade® (oxymetazoline hydrochloride) cream, 1% and additional intellectual property. The acquisition includes an exclusive license to certain intel
- Pre-conditioning Added to Sebacia Microparticles Enhances Outcomeshttps://practicaldermatology.com/news/pre-conditioning-added-to-sebacia-microparticles-enhances-outcomes/2457567/Using pre-conditioning in conjunction with Sebacia Microparticles for treatment of acne leads to enhanced outcomes, new data suggest. In fact, results from a real-world, pre-conditioning registry trial in Europe demonstrate that the combination of pre-conditioning followed by Sebacia Mi
- Endo Presents Data on the Perception and Measurement of Cellulite Severity at ASDS Meetinghttps://practicaldermatology.com/news/endo-presents-data-on-the-perception-and-measurement-of-cellulite-severity-at-asds-meeting/2457568/The new Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) is a reliable tool for evaluating cellulite severity of the buttocks and thighs and correlates well with the Patient Reported Photonumeric Cellulite Severity Scale, according to research presented by